Dedicated to discovering, developing, and commercializing novel therapeutics to transform the treatment of patients with grievous blood-based disorders

Global Blood Therapeutics, Inc. (NASDAQ: GBT) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease. GBT is also investigating GBT440 for the treatment of hypoxemic pulmonary disorders in two ongoing Phase 2a studies in patients with idiopathic pulmonary fibrosis.

Year Invested: 2012
Location: South San Francisco, Calif.

Recent News

March 29, 2017
Global Blood Therapeutics to Present at the 16th Annual Needham Healthcare Conference

March 13, 2017
Global Blood Therapeutics Reports Recent Business Progress and Fourth Quarter and Year-End 2016 Financial Results

March 1, 2017
Global Blood Therapeutics Announces Participation at Two Upcoming Investor Conferences in March

Read More News

Associated Team Members

Kevin Starr

Mark A. Goldsmith, M.D., Ph.D.
Venture Partner

Craig Muir
Partner/Chief Technology Officer

Charles Homcy, M.D.

Glenn Pierce, M.D., Ph.D.